Ureterovesical Fistula — Cost, Top Hospitals & Success Rates | MyMedicPlus

A ureterovesical fistula (UVF) is an abnormal epithelialised tract connecting the ureter — specifically its distal segment near the ureterovesical junction (UVJ) — to the urinary bladder, or, in some definitions, from the ureter to any adjacent pelvic organ through the bladder wall. This rare condition disrupts the normal anatomical boundaries between the ureter and bladder, creating an aberrant channel through which urine can flow in either direction, and through which bacteria, gas, or fistula-derived secretions may pass.

UVF must be distinguished from the more common vesicovaginal fistula (VVF) and ureterovaginal fistula (a communication between the ureter and vagina, typically from distal ureteral injury during hysterectomy) as the clinical presentation and management differ significantly. True ureterovesical fistulae in which the distal ureter communicates internally with the bladder through a pathological channel — rather than through the normal UVJ — are among the rarest pelvic fistulae encountered in urological practice.

The condition is characterised by a clinical triad of symptoms arising from the abnormal communication: recurrent urinary tract infections (as gut flora gain bladder access in enteric-related fistulae), pneumaturia (passage of gas in the urine — pathognomonic of a fistula involving the bowel through the urinary tract), haematuria, and flank or pelvic pain from associated ureteral obstruction. In radiation-induced cases, symptoms may evolve insidiously years after the original treatment.

Management is inherently complex because UVF virtually always occurs in a background of prior pelvic surgery, radiotherapy, malignancy, or infection — all of which compromise tissue quality, vascularity, and healing capacity. Surgical repair principles centre on complete fistula excision, tension-free re-anastomosis or reimplantation of healthy ureteral tissue, and interposition of well-vascularised tissue to reduce recurrence risk.

Ureterovesical fistulae are almost exclusively secondary to another disease process or prior intervention. Understanding the aetiology is essential to planning appropriate management, as the underlying cause directly affects tissue quality, surgical approach, and prognosis.

Iatrogenic (Post-Surgical) — Most Common

Pelvic surgery — particularly radical hysterectomy (Wertheim procedure) for cervical cancer, radical cystectomy, anterior resection for rectal cancer, pelvic floor reconstruction, and ureteroscopy — accounts for the majority of iatrogenic ureteral injuries and subsequent fistulae. Ureteral injuries from gynaecological surgery are estimated to occur in 0.5–2.5% of radical hysterectomies. When ureteral injury at or near the UVJ is not recognised intraoperatively and repaired immediately, the devascularised or partially transected ureter undergoes necrosis, with subsequent urinoma formation and fistulisation to the bladder or vagina. A ureterovesical fistula results when the urine collection fistulises specifically through the posterior or lateral bladder wall rather than to the vagina.

Radiation-Induced

Pelvic irradiation for gynaecological (cervical, endometrial, vaginal), rectal, or urological malignancies produces progressive obliterative endarteritis that can cause delayed ureteral ischaemia and necrosis months to years after treatment completion. Radiation-induced fistulae are particularly challenging because the surrounding tissues are hypovascular, fibrotic, and poorly healing — making primary repair unreliable without interposition of non-irradiated tissue. The interval from radiotherapy to fistula presentation ranges from 6 months to over 10 years, with a median of approximately 2 years for high-dose pelvic radiation.

Malignant Infiltration

Advanced or recurrent pelvic malignancies (cervical, rectal, bladder, prostate) can invade the distal ureter and create a pathological communication with the bladder. In these cases, fistula repair is not curative and management must be integrated with the oncological treatment plan. Urinary diversion (nephrostomy or ureteral stenting) is the primary goal to preserve renal function and quality of life while systemic or further local treatment is delivered.

Inflammatory and Infective

Crohn's disease with terminal ileal or sigmoid involvement can fistulise to the ureter and then to the bladder. Diverticulitis with colovesical fistula occasionally involves the ureter at the bladder wall. Pelvic actinomycosis and tuberculous ureteritis are rare infectious causes.

Traumatic

Penetrating pelvic trauma (stab wounds, gunshot wounds) and blunt trauma with pelvic fractures can injure the distal ureter and bladder simultaneously, creating conditions for fistula formation if the injury is not completely repaired.

Accurate diagnosis of a ureterovesical fistula requires systematic imaging and endoscopic evaluation to define the fistula anatomy, assess the upper urinary tract, and plan surgical repair. No single investigation is sufficient — a combination of modalities is required.

Clinical Assessment

Patients typically present with symptoms 1–3 weeks after pelvic surgery (iatrogenic cases) or insidiously in radiation or malignant cases. Key symptoms include:

• Persistent urinary leak (per vaginum in associated vesicovaginal fistulae, or as continuous or positional incontinence)
• Pneumaturia — strongly suggests enteric fistula component
• Recurrent febrile UTIs with atypical organisms (enteric fistulae)
• Flank pain and hydronephrosis (associated ureteral obstruction)
• Haematuria
• Rising creatinine (when associated with ureteral obstruction)

Imaging Investigations

• CT urography (CTU): The investigation of first choice. Multi-phase CT with urographic phase imaging defines the site of ureteral injury or fistula, associated hydronephrosis, urinoma, and the relationship of the ureter to adjacent structures. Contrast extravasation at the UVJ or distal ureter confirms ureteral injury. CTU accurately assesses the upper urinary tract in addition to pelvic anatomy.
• Retrograde ureterogram: A catheter is placed into the ureteral orifice at cystoscopy and contrast instilled to fill the ureter under fluoroscopy. This is the most sensitive test for defining the exact level and extent of ureteral disruption and any fistulous tract. Contraindicated in active UTI.
• Technetium-99m renal scintigraphy (MAG3 or DTPA): Quantifies differential renal function and obstruction grade; essential when considering long-term management in a compromised kidney.
• MRI pelvis: Superior to CT for soft tissue characterisation, particularly in radiation-injured tissue and where malignant recurrence needs excluding. Diffusion-weighted sequences help distinguish radiation fibrosis from tumour.

Endoscopic Assessment

Cystoscopy is performed under general anaesthesia to inspect the bladder mucosa for fistula orifices, assess the ureteral orifices (which may be oedematous, displaced, or absent on the affected side), and take biopsies of any suspicious tissue. The appearance of the fistula opening — whether surrounded by healthy, irradiated, or malignant mucosa — directly influences surgical planning. Ureteral stent placement at cystoscopy may decompress the obstructed kidney pre-operatively.

Treatment of ureterovesical fistula is tailored to the underlying aetiology, the quality of surrounding tissue, the patient's general condition and oncological status, and the functional status of the affected kidney.

Pre-Operative Optimisation

Before definitive repair, the upper urinary tract must be decompressed and infection controlled. Options for temporary urinary diversion include:

• Percutaneous nephrostomy: A radiologically guided drain placed through the flank into the renal pelvis. This immediately decompresses an obstructed kidney and diverts urine away from the fistula, allowing oedema and inflammation to settle before surgery. Nephrostomy urine culture guides antibiotic selection.
• Retrograde ureteral stent: If cystoscopic access allows, a double-J stent (indwelling ureteral stent) across the injury may permit temporary splintage and healing of minor partial disruptions. This is not appropriate for complete ureteral disruption or established fistulae.

Conservative Management (Selected Cases)

Very small, early fistulae from partial ureteral lacerations — typically identified within 24–48 hours of surgery — may be managed with prolonged catheter drainage (2–6 weeks) and nephrostomy diversion to reduce pressure at the leak site. This approach is successful in a minority of cases and is not appropriate for established, epithelialised fistulae.

Surgical Repair — Principles

The cornerstone of surgical repair is excision of the fistulous tract, debridement of all devascularised or irradiated tissue, and tension-free anastomosis of healthy ureteral tissue to the bladder. Key surgical principles include:

• Adequate ureteral mobilisation: Sufficient ureteral length must be achieved for a tension-free anastomosis. When the distal ureteral segment is too short, damaged, or irradiated, a psoas hitch (suturing the bladder to the psoas muscle to bring it closer to the ureter) or a Boari flap (a pedicled flap of bladder wall rolled into a tube to bridge a gap of 10–15 cm) provides additional reach.
• Ureteral reimplantation: The healthy proximal ureteral end is reimplanted into the bladder using a submucosal tunnel technique (Lich-Gregoir extravesical or intravesical approaches). A ureteral stent is left across the anastomosis for 4–6 weeks.
• Tissue interposition: In irradiated fields, a pedicled omental flap, peritoneal flap, or Martius labial fat pad graft is interposed between the repair and the vagina or bowel to introduce new blood supply and reduce re-fistulation risk. This is mandatory in radiation-induced fistulae.
• Minimally invasive approaches: Laparoscopic and robot-assisted repair of ureterovesical fistulae have been reported in centres with advanced urological laparoscopic expertise, with comparable outcomes to open repair in non-irradiated cases.

Urinary Diversion (Palliative)

In patients with malignant fistulae not amenable to curative repair, or in poor surgical candidates, permanent nephrostomy or ureteral cutaneous diversion provides palliation by diverting urine away from the fistula, controlling pain, infection, and urinary leakage while systemic cancer treatment is delivered.

Successful surgical repair of a ureterovesical fistula restores normal urinary anatomy, eliminates the source of recurrent infection and urinary leakage, and preserves ipsilateral renal function.

Fistula Closure

In iatrogenic fistulae repaired in healthy (non-irradiated, non-malignant) tissue, primary repair success rates of 85–95% are reported. Techniques using psoas hitch or Boari flap achieve similar success rates when a tension-free anastomosis is achieved with adequate ureteral blood supply. Omental interposition in radiation cases improves primary repair success to approximately 70–80% — still significantly superior to outcomes without vascularised interposition (<50%).

Renal Function Preservation

Timely repair before the ipsilateral kidney has undergone irreversible damage from prolonged obstruction is critical. Renal function typically recovers substantially following fistula repair when the kidney was not severely compromised pre-operatively. MAG3 renography performed 3 months post-repair quantifies recovery of differential renal function. Kidneys with <10% differential function pre-repair often do not recover meaningfully and may be better managed by nephrectomy to eliminate the diseased unit.

Quality of Life

Elimination of urinary leakage, pneumaturia, and recurrent sepsis has a profound positive impact on quality of life. Patient-reported outcomes consistently demonstrate major improvements in physical function, emotional wellbeing, and social participation following successful fistula repair. Even in oncological settings, palliation of distressing fistula symptoms through nephrostomy diversion significantly improves end-of-life quality of life when curative repair is not possible.

Surgery for ureterovesical fistula carries a higher risk profile than elective ureteral reimplantation because it is performed in the context of prior pelvic surgery, radiation injury, or malignancy — all of which impair tissue healing and increase technical difficulty.

General Surgical Risks

• Bleeding and haematoma in the previously operated or irradiated pelvis (dense adhesions increase risk)
• Infection (wound infection, pelvic abscess) — increased in irradiated or immunocompromised patients
• Ileus and prolonged bowel recovery from pelvic dissection
• Deep vein thrombosis / pulmonary embolism (prolonged pelvic dissection, oncological patients)

Fistula-Specific Risks

• Fistula recurrence / repair failure: The most significant risk, particularly in irradiated tissue. Rates of 20–30% in radiation-induced cases without omental interposition; 10–20% with interposition. Requires repeat imaging, decompression, and further surgical planning.
• Ureteral anastomotic stricture: Scarring at the ureteral reimplantation site causes obstruction and hydronephrosis, requiring balloon dilation, endoureterotomy, or revision reimplantation.
• Ipsilateral renal loss: If the ipsilateral kidney is severely compromised (GFR <10 ml/min/1.73m², hydronephrotic, chronically infected), nephrectomy may be the safest management rather than complex repair of a non-functioning unit.
• Contralateral ureteral injury: Dissection in a scarred pelvis risks inadvertent injury to the contralateral ureter — potentially the only functioning kidney. The contralateral ureter should be stented prophylactically at the outset of surgery in complex cases.
• Bladder dysfunction: Extensive bladder dissection for psoas hitch or Boari flap can transiently impair bladder capacity and compliance.

Radiation-Specific Complications

Radiation damage to the ureter and bladder is ongoing and progressive. Patients who undergo technically successful repair may develop new radiation-related complications — including bladder contracture, haematuria, secondary fistulae to other pelvic structures, and rectal injury — in the months to years following ureterovesical fistula repair. Long-term urological surveillance is mandatory in all patients with a history of pelvic radiation.

Recovery following ureterovesical fistula repair is typically longer and more complex than elective ureteral surgery due to the underlying disease burden and extent of surgical dissection required.

Immediate Post-Operative Period

Patients are managed with an indwelling urethral catheter for 10–14 days and a ureteral stent across the anastomosis for 4–6 weeks. A pelvic drain is maintained until drainage is minimal and amylase-negative (confirming no pancreatic injury) and creatinine-negative (confirming no urine leak from the repair). Intravenous antibiotics are administered perioperatively and continued orally based on pre-operative culture sensitivities. Patients typically require 5–10 days of hospital admission, longer in irradiated or frail patients.

Stent and Catheter Management

The ureteral stent is removed at cystoscopy at 4–6 weeks, once the anastomosis has healed. Before stent removal, a retrograde ureterogram may be performed through the stent to confirm anastomotic integrity. The urethral catheter is removed the day after the retrograde ureterogram confirms no leak, and patients are asked to demonstrate satisfactory voiding before discharge. A formal cystogram or CT urogram is performed at 6–8 weeks post-repair to confirm fistula closure.

Upper Tract Surveillance

Following stent removal, renal ultrasound is performed at 6 weeks, 3 months, and 6 months to exclude developing hydronephrosis from anastomotic stricture. If hydronephrosis develops, early intervention (balloon dilation or stent reinsertion) prevents progressive renal function loss. MAG3 renography at 3 months documents recovery of ipsilateral renal function compared to pre-operative baseline.

Oncological Co-Management

In patients with radiation-induced or malignant fistulae, urological follow-up must be coordinated with the oncology team. Restoration of urinary drainage by fistula repair or nephrostomy allows delivery of systemic chemotherapy or further radiotherapy in selected patients. Planned surveillance imaging (CT chest/abdomen/pelvis, tumour markers) continues according to the oncological protocol.

Patients should be counselled that long-term surveillance is required — fistula recurrence, new contralateral disease, and progressive radiation cystitis are potential late complications requiring proactive monitoring rather than reassurance based on initial successful repair.

Surgery for ureterovesical fistula is a complex, specialised procedure typically performed at tertiary urology or urogynecology centres. Costs reflect the need for a multidisciplinary team including urologists, gynaecological oncologists, colorectal surgeons (for enteric fistulae), and specialist anaesthesia.

Approximate Cost Ranges by Region

• United States: USD 20,000–60,000 for open surgical repair (highly variable based on complexity, hospital admission length, and whether reconstruction such as Boari flap or omental interposition is required)
• United Kingdom (private / NHS tertiary): GBP 10,000–25,000
• India (specialist centres, JCI/NABH): USD 4,000–10,000 (open repair with pelvic reconstruction); USD 6,000–15,000 (complex radiation cases)
• Thailand: USD 8,000–18,000
• Turkey: USD 6,000–14,000
• Singapore: USD 12,000–30,000

Key Cost Drivers

• Aetiology: Radiation-induced cases are disproportionately expensive due to prolonged hospital admission, need for omental or flap interposition, and higher rates of complications requiring re-intervention
• Oncological context: Patients with active malignancy require concurrent oncological management that substantially increases the total episode cost
• Reconstruction extent: Psoas hitch alone is less expensive than Boari flap; omental interposition adds operative time and surgical complexity
• ICU/HDU admission: Complex pelvic fistula surgery in frail or radiation-damaged patients may require high-dependency nursing post-operatively
• Pre-operative imaging: CTU, MRI pelvis, and nuclear medicine studies (MAG3) each add USD 500–2,000 to the diagnostic workup cost

Given the rarity and complexity of ureterovesical fistulae, patients considering treatment abroad should prioritise centres with documented experience in pelvic fistula surgery, available multidisciplinary oncological support if malignancy is involved, and clear protocols for managing complications including fistula recurrence. Outcome data and complication rates should be requested and reviewed before committing to an international referral.

True ureterovesical fistulae virtually never resolve without intervention. The following alternatives to definitive surgical repair are appropriate in specific clinical scenarios.

Temporary Conservative Management with Drainage

Very small iatrogenic partial ureteral lacerations — identified within 24–72 hours of the original surgery — may be managed conservatively with percutaneous nephrostomy drainage and an indwelling urethral catheter for 4–6 weeks. This permits spontaneous healing in a small minority of cases (<20% for established fistulae). This approach is unreliable and should only be attempted when the fistula is partial and the surrounding tissue is healthy and well-vascularised. If the fistula does not close within 6 weeks of conservative management, definitive surgical repair should proceed.

Endoscopic Approaches

Endoscopic management — placement of a double-J ureteral stent across the fistula to divert urine — occasionally succeeds in splinting a partial injury and allowing healing, particularly in iatrogenic cases presenting early. Cystoscopic fulguration (cauterisation) of the fistula opening has been described but is rarely effective alone for established ureterovesical fistulae. Endoscopic treatment is a temporising measure rather than definitive cure and should be accompanied by nephrostomy decompression.

Long-Term Nephrostomy Drainage (Palliative)

In patients with malignant fistulae from non-resectable pelvic cancer, active systemic infection, or who are unfit for general anaesthesia and pelvic surgery, long-term percutaneous nephrostomy diverts urine from the fistula, controls sepsis, and preserves renal function without surgical repair. Nephrostomy tubes require regular exchange every 3 months to prevent encrustation and infection. Quality of life with a nephrostomy is reduced compared to internal drainage but is significantly better than the alternative of uncontrolled sepsis and progressive renal failure from an untreated fistula.

Palliative Radiotherapy

For malignant fistulae arising from radiation-naive tumours infiltrating the ureterovesical junction, palliative radiotherapy can reduce tumour bulk and occasionally close a malignant fistula while providing local disease control. This is rarely curative but may extend the interval before surgical intervention is required.

Systemic Oncological Treatment

In chemotherapy-sensitive tumours (e.g., advanced cervical or rectal cancer), systemic treatment combined with nephrostomy diversion can achieve tumour regression and, occasionally, fistula closure. This is most relevant in patients who have not previously received systemic therapy and who have good functional status. Oncological response must be confirmed by imaging before considering repair of a previously malignant fistula.